Advertisement
U.S. markets open in 1 hour 40 minutes
  • S&P Futures

    5,303.00
    -5.25 (-0.10%)
     
  • Dow Futures

    40,121.00
    -23.00 (-0.06%)
     
  • Nasdaq Futures

    18,478.00
    -25.75 (-0.14%)
     
  • Russell 2000 Futures

    2,139.50
    +1.10 (+0.05%)
     
  • Crude Oil

    82.46
    +1.11 (+1.36%)
     
  • Gold

    2,228.50
    +15.80 (+0.71%)
     
  • Silver

    24.62
    -0.13 (-0.53%)
     
  • EUR/USD

    1.0790
    -0.0040 (-0.37%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    13.03
    +0.25 (+1.96%)
     
  • GBP/USD

    1.2619
    -0.0019 (-0.15%)
     
  • USD/JPY

    151.3840
    +0.1380 (+0.09%)
     
  • Bitcoin USD

    70,640.03
    +347.77 (+0.49%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.37
    +20.39 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

The Zacks Analyst Blog Highlights: IBM, Texas Instruments, Glaxo, Simon Property Group and State Street

The Children's Place, Inc. (PLCE) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front

For Immediate Release

Chicago, IL – August 21, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include IBM IBM, Texas Instruments TXN, Glaxo GSK, Simon Property Group SPG and State Street STT.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Monday’s Analyst Blog:

Top Stock Reports for IBM, Texas Instruments and Glaxo

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including IBM, Texas Instruments and Glaxo. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

IBM’s shares have underperformed the broader market on a year-to-date basis, losing -4.8% vs. the S&P 500’s +6.8% gain. IBM provides advanced information technology solutions, including computer systems, software, storage systems and microelectronics.

The company benefits from strong demand for z14 Mainframe and Power products. Moreover, IBM’s improving position in the cloud, security and analytics bodes well. Also, accretive acquisitions have expanded IBM’s product portfolio into higher-growth segments, such as cloud computing, AI and Big Data.

However, the Zacks analyst thinks the strategic imperatives will take some more time to report meaningful growth and offset weakness in the traditional business. IBM’s ongoing heavily time-consuming business model transition to cloud continues to hurt the stock.

(You can read the full research report on IBM here >>>).

Shares of Buy-ranked Texas Instruments have gained +37.2% in the past year, underperforming the Zacks General Semiconductor industry which has gained +40.1% over the same period. Texas Instruments reported robust second-quarter results on the back of strength in auto and industrial markets.

The company continues to prudently invest its R&D dollars in several high margin, high-growth areas of the analog and embedded processing markets. The Zacks analyst thinks this is gradually increasing its exposure to industrial and automotive markets and dollar content at customers, while reducing exposure to volatile consumer/computing markets.

Margins continue to expand on secular strength in the auto and industrial markets and manufacturing efficiencies that include growing 300-millimeter Analog output. Continuous dividend hike is a big positive. However, increasing competition, unfavorable currency effect and a high debt load remain concerns.

(You can read the full research report on Texas Instruments here >>>).

Glaxo’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry year to date, gaining +16.3% versus the industry’s +4.8% increase. Glaxo beat estimates for earnings and sales in Q2 and raised its earnings growth expectations for the year. The Zacks analyst thinks the performance of Glaxo’s new products has been encouraging.

Meanwhile, a strong start to its three newest products — Trelegy Ellipta, Shingrix and Juluca — and buy in of Novartis’ stake in the Consumer Healthcare JV have strengthened Glaxo’s competitive position. However, persistent challenges like stiff competition, genericization and pricing pressure are hurting sales. Particularly, pricing pressure and competitive dynamics are hurting sales of Glaxo’s inhaled respiratory products, particularly the older ones.

Its top-selling product, Advair, is also expected to face generic competition in the United States this year, which will further hurt sales. The slowdown in sales of the Consumer Healthcare segment is also a concern.

(You can read the full research report on Glaxo here >>>).

Other noteworthy reports we are featuring today include Simon Property Group and State Street.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com/

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
International Business Machines Corporation (IBM) : Free Stock Analysis Report
 
State Street Corporation (STT) : Free Stock Analysis Report
 
GlaxoSmithKline plc (GSK) : Free Stock Analysis Report
 
Texas Instruments Incorporated (TXN) : Free Stock Analysis Report
 
Simon Property Group, Inc. (SPG) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Advertisement